Stochastic Resonance Stimulation Effect on Gait Stability in Parkinson Disease
The Role of Sensory Deficits in the Neural Control of Balance During Walking in Parkinson's Disease
1 other identifier
interventional
21
1 country
1
Brief Summary
The present study explored the use of a technique called stochastic resonance (SR) stimulation that may help individuals with Parkinson Disease maintain balance while walking on challenging surfaces. Impaired balance represents one of the disease symptoms, putting people at risk for falls, partly due to impaired processing of sensory information. SR uses light electrical signals to improve the way the body detects sensations. We wanted to test if SR could help people with Parkinson disease stay steadier while walking. Each participant's optimal SR intensity was determined before they walked on a treadmill in a virtual environment that created visual disturbances to challenge their balance. We measured how much their body swayed, how they placed their feet, and how their ankles moved during the walking tasks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable parkinson-disease
Started May 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 13, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 13, 2022
CompletedFirst Submitted
Initial submission to the registry
February 3, 2025
CompletedFirst Posted
Study publicly available on registry
February 17, 2025
CompletedFebruary 17, 2025
February 1, 2025
1.6 years
February 3, 2025
February 10, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Change in the Center of Mass (CoM) excursion
For the visual perturbation trials, we will use CoM excursion as the primary outcome measure since it has been used in prior studies in children and adults using visual perturbation protocols. This is determined by comparing the average CoM during perturbed steps to non-perturbed steps for each participant, integrated across the first eight steps initiated by the heel strike that triggered the stimulus. We will measure CoM using kinetics and kinematic computed through a motion capture system(Qualysis). For the unperturbed trials, we will use margin of stability (MoS) as the primary outcome measure. MOS refers to the distance between extrapolated center of mass, which includes center of mass position and velocity, and the base of support. It has been previously used to measure balance in children with cerebral palsy and Parkinson Disease.
Through study completion, an average of 1 year.
Study Arms (2)
Stochastic Resonance (SR)
EXPERIMENTALDuring this condition, participants will walk on the treadmill while receiving SR stimulation at their individual optimal intensity (SR) with and without visual perturbations.
No Stochastic Resonance (no-SR)
NO INTERVENTIONDuring this condition, participants will walk on the treadmill while receiving no SR stimulation (no-SR) with and without visual perturbations.
Interventions
The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of Parkinson Disease
- Hoehn and Yahr (H\&Y) stage ≤ III
- Can walk independently for at least 2 minutes without an assistive device or orthosis
- Ability to communicate discomfort during testing
- Can follow multi-step commands
- Scored at least 24/30 on the Montreal Cognitive assessment (MoCA)
You may not qualify if:
- Any head, neck, or face injury in the six months prior to the study (e.g., concussion, eye injury)
- History of vestibular or ocular dysfunction
- Currently taking any medications affecting balance (i.e. antibiotics)
- Injuries to lower extremities affecting balance in the past six months
- Pregnancy
- Any neurological disorders other than Parkinson's disease (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 minutes, CNS neoplasm, history of stroke)
- Unstable cardiac or pulmonary disease
- Clinically obese (BMI 30 or above)
- Any metal implant in the feet or legs that is close to the stimulating electrodes
- A known allergy to medical-grade adhesives
- Any other comorbidity affecting the ability to safely walk without assistance for at least 2 minutes
- Exhibited severe dyskinesia
- Did not respond to L-DOPA or other dopaminergic treatment
- Exhibited cardiovascular-autonomic or multiple-system symptoms indicative of a "Parkinsonism-plus" presentation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Delawarelead
- Parkinson's Foundationcollaborator
Study Sites (1)
University of Delaware
Newark, Delaware, 19713, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
John J Jeka, PhD
University of Delaware
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2025
First Posted
February 17, 2025
Study Start
May 19, 2021
Primary Completion
December 13, 2022
Study Completion
December 13, 2022
Last Updated
February 17, 2025
Record last verified: 2025-02